AL Amyloidosis Market Report 2026

AL Amyloidosis Market Overview

• AL Amyloidosis market size has reached to $3.51 billion in 2025 • Expected to grow to $6.38 billion in 2030 at a compound annual growth rate (CAGR) of 12.6% • Growth Driver: Rising Incidence Of Plasma Cell Disorders Driving Market Growth • Market Trend: Development Of Next-Generation CAR T-Cell Therapies • North America was the largest region in 2025.

What Is Covered Under AL Amyloidosis Market?

AL Amyloidosis is a rare and serious condition where abnormal proteins, called light chains, are produced by plasma cells in the bone marrow. These light chains misfold and form amyloid fibrils, which then deposit in various organs and tissues, impairing their function. Commonly affected organs include the heart, kidneys, liver, and nervous system. Symptoms vary depending on the organs involved but may include fatigue, swelling, shortness of breath, numbness, and organ dysfunction. The main types of treatment for AL amyloidosis includes various therapies, including chemotherapy, supportive care, surgery, stem cell transplant, and targeted therapy. Chemotherapy involves powerful drugs targeting amyloid deposits, aiming to reduce symptoms and improve survival. These drugs include transthyretin transport inhibitors, immunomodulatory drugs, monoclonal antibodies, and proteasome inhibitors. Administration of these drugs can be through intravenous or oral routes. In terms of distribution channels, they are typically available via hospital pharmacies, retail pharmacies, and online pharmacies, which allow access to medications based on patients' needs and convenience.

What Is The AL Amyloidosis Market Growth Forecast?

The al amyloidosis market size is expected to see rapid growth in the next few years. It will grow to $6.38 billion in 2030 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to development of novel targeted therapies, increasing adoption of monoclonal antibodies and proteasome inhibitors, expansion of stem cell transplant programs, rising healthcare infrastructure for rare diseases, improved diagnostic technologies for early detection. Major trends in the forecast period include increasing adoption of targeted therapies for al amyloidosis, rising use of monoclonal antibodies and proteasome inhibitors, expansion of stem cell transplant procedures, growing focus on organ-specific supportive care, increased awareness and early diagnosis of al amyloidosis.

Global AL Amyloidosis Market Segmentation

1) By Treatment: Chemotherapy, Supportive Care, Stem Cell Transplant, Targeted Therapy 2) By Drugs: Immunomodulatory Drugs, Monoclonal Antibodies, Proteasome Inhibitors, Other Drugs 3) By Route Of Administration: Intravenous, Oral 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies Subsegments: 1) By Chemotherapy: Conventional Chemotherapy Agents, High-Dose Chemotherapy 2) By Supportive Care: Pain Management, Organ-specific Supportive Care (Cardiac, Renal) 3) By Stem Cell Transplant: Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant 4) By Targeted Therapy: Monoclonal Antibodies, Proteasome Inhibitors, Kinase Inhibitors

What Is The Driver Of The AL Amyloidosis Market?

The rising incidence of plasma cell disorders is expected to propel the growth of the AL amyloidosis market going forward. Plasma cell disorders are conditions where abnormal plasma cells produce excessive or abnormal antibodies, potentially causing organ damage. The rising incidence of plasma cell disorders is attributed to factors such as an aging population, increased life expectancy, and advancements in diagnostic technologies. AL amyloidosis is a condition that arises from plasma cell disorders, specifically the overproduction of abnormal light chain proteins, which can lead to the accumulation of amyloid deposits in organs and tissues, further exacerbating the effects of plasma cell dyscrasias. For instance, in August 2024, according to the reports published by The American Cancer Society (ACS), a US-based nonprofit organization, in 2024, about 35,780 new cases of multiple myeloma are expected to be diagnosed (19,520 in men and 16,260 in women), and around 12,540 deaths are projected, with 7,020 in men and 5,520 in women. Therefore, the rising incidence of plasma cell disorders is driving the growth of the AL amyloidosis industry.

Key Players In The Global AL Amyloidosis Market

Major companies operating in the al amyloidosis market are Johnson & Johnson, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Pfizer Inc., Amgen Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Roche Holding AG, Novartis AG, Merck & Co. Inc., Eli Lilly and Company, GlaxoSmithKline plc, Genmab A/S, Prothena Corporation plc, BridgeBio Pharma Inc., Oncopeptides AB, Ionis Pharmaceuticals Inc., Neurimmune AG, Immix Biopharma Inc., Attralus Inc.

Global AL Amyloidosis Market Trends and Insights

Major companies operating in the AL amyloidosis market are focusing on developing innovative therapies such as next-generation B-cell maturation antigen (BCMA)-directed CAR T-cell therapy to improve treatment efficacy and patient outcomes. Next-generation BCMA-directed CAR T-cell therapy refers to an advanced form of immunotherapy that involves engineering a patient's T cells to target and attack BCMA on the surface of cancer cells, specifically in multiple myeloma. For instance, in September 2023, Immix Biopharma Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for NXC-201 for the treatment of a life-threatening blood disorder, Amyloid Light Chain (AL) Amyloidosis. NXC-201 is a next-generation CAR-T cell therapy being tested in clinical trials for the treatment of amyloid light chain (AL) amyloidosis, showing promising results with a 100% hematologic response rate and organ improvements in patients who had failed previous treatments.

What Are Latest Mergers And Acquisitions In The AL Amyloidosis Market?

In November 2024, Stand Up To Cancer (SU2C), a US-based non-profit organization, partnered with Johnson & Johnson Inc. to introduce novel treatments for AL amyloidosis. With this partnership, Stand Up To Cancer and Johnson & Johnson aim to advance research on the combination of teclistamab and daratumumab as a treatment for AL amyloidosis, a rare and difficult-to-treat disease, in order to improve therapeutic options for affected patients. Johnson & Johnson Inc. is a US-based healthcare company that specializes in providing treatment for AL amyloidosis.

Regional Outlook

North America was the largest region in the AL amyloidosis market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the AL Amyloidosis Market?

The AL amyloidosis market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, monitoring and follow-up services, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The AL amyloidosis market also includes sales of proteasome inhibitors, monoclonal antibodies, diagnostic tests, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the AL Amyloidosis Market Report 2026?

The al amyloidosis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the al amyloidosis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.